Walleye Capital’s Edgewise Therapeutics EWTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$370K Buy
+9,125
New +$388K ﹤0.01% 4331
2025
Q3
– Sell
-86,882
Closed -$1.14M – 4660
2025
Q2
$1.14M Buy
86,882
+70,704
+437% +$1.02M ﹤0.01% 1947
2025
Q1
$356K Sell
16,178
-182,484
-92% -$4.79M ﹤0.01% 2825
2024
Q4
$5.3M Sell
198,662
-43,589
-18% -$1.39M 0.01% 1031
2024
Q3
$6.47M Buy
+242,251
New +$4.82M 0.01% 990
2022
Q3
– Sell
-17,000
Closed -$135K – 3310
2022
Q2
$135K Sell
17,000
-8,196
-33% -$61.9K ﹤0.01% 1657
2022
Q1
$244K Buy
+25,196
New +$324K 0.01% 1415

Other funds holding EWTX

Walleye Capital's EWTX Position: Q3 2026 in Review

Walleye Capital opened a new position in Edgewise Therapeutics (EWTX) in Q3 2026: 9,125 shares worth $370K. The stake represents ﹤0.01% of the portfolio and ranks #4331 among its holdings. This is a return to the name: Walleye Capital previously reported a position in EWTX as recently as Q2 2025.

Walleye Capital first reported a position in EWTX in Q1 2022 and has held it in 7 quarters since. The position peaked at $6.47M in Q3 2024. 253 funds tracked by Wall St. Rank hold EWTX as of Q3 2026.

  • Walleye Capital held 9,125 shares of Edgewise Therapeutics worth $370K as of Q3 2026.
  • Edgewise Therapeutics was a new Walleye Capital position in Q3 2026.
  • Edgewise Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #4331 holding.
  • Walleye Capital first reported a position in Edgewise Therapeutics in Q1 2022 and has held it in 7 quarters since.
  • Walleye Capital's Edgewise Therapeutics position peaked at $6.47M in Q3 2024.
  • 253 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.